Correction to: Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma

Laura Amanda Vallejo-Aparicio (), Jesús Molina, Iñigo Ojanguren, Ana Viejo Casas, Alicia Huerta and Henrik Svedsater
Additional contact information
Laura Amanda Vallejo-Aparicio: Market Access, GSK (GlaxoSmithKline)
Jesús Molina: Centro de Salud Francia
Iñigo Ojanguren: Hospital Universitario Vall d’Hebron
Ana Viejo Casas: Centro de Salud Pisueña Cayon
Alicia Huerta: Market Access, GSK (GlaxoSmithKline)
Henrik Svedsater: Value Evidence and Outcomes, GSK

The European Journal of Health Economics, 2020, vol. 21, issue 3, No 13, 475-475

Abstract: In the published article, the Table 1 was published incorrectly.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-019-01137-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:21:y:2020:i:3:d:10.1007_s10198-019-01137-z

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-019-01137-z

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().